Since it exerts a stronger antitumor action than predinisolone, dexamethasone was used for therapy of patients with non-Hodgkin's lymphoma refractory to CHOP. All patients (66), resistant to CHOP, suffered bone marrow involvement. Dexamethasone pulsed therapy was given to 45 patients, with 21 COP-BLAM or ASHAP, MAD, Dexa-BEAM treated in control. Median response duration in high- and low-grade non-Hodgkin's lymphoma groups was 2 and 12 months, respectively.
Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
high- low-grade
8
low-grade non-hodgkin's
8
therapy patients
8
non-hodgkin's lymphoma
8
[use dexamethasone
4
dexamethasone treatment
4
treatment high-
4
non-hodgkin's lymphoma]
4
lymphoma] exerts
4
exerts stronger
4
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!